No Data
No Data
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Truist Securities: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $60.00.
Truist Securities: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $60.00.
Truist Securities Maintains Buy on Adverum Biotechnologies, Maintains $60 Price Target
Truist Securities analyst Joon Lee maintains Adverum Biotechnologies with a Buy and maintains $60 price target.
Adverum Biotechnologies (ADVM) Receives a Buy From Truist Financial
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress